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INTRODUCTION
Spinal and bulbar muscular atrophy (SBMA) is a slowly progressive
adult onset neurodegenerative disease that affects men in mid-life.
The disease causes degeneration and atrophy of the muscles of the
proximal limb girdle and the bulbar muscles of the jaw (Kennedy
et al., 1968), as well as the accumulation of nuclear aggregates of
mutant androgen receptor (AR) protein, otherwise known as
neuronal intranuclear inclusions (NIIs) (Li et al., 1998). SBMA
results from a CAG expansion in the first exon of the AR gene,
located on the proximal long arm of the X chromosome (La Spada
et al., 1991). In the rare instances when female carriers manifest
disease, their symptoms are mild (Ferlini et al., 1995). Initially, it
was unclear whether female carriers were protected from disease
symptoms owing solely to X-inactivation. However, the finding of
homozygous females with very mild symptoms (Schmidt et al.,
2002) and evidence from several cell and animal models of SBMA
indicate that testosterone plays a crucial and causative role in
disease pathogenesis. Cellular models of disease show an increase
in nuclear inclusion formation upon hormone treatment (Stenoien
et al., 1999; Walcott and Merry, 2002), whereas fly models
demonstrate that consumption of testosterone induces disease as
well as nuclear inclusion formation (Takeyama et al., 2002).
Transgenic mouse models have indicated that both surgical and
chemical castration of SBMA males alleviates or prevents disease
progression, depending on the stage of disease at the time of
intervention (Katsuno et al., 2002; Katsuno et al., 2003; Chevalier-
Larsen et al., 2004). Furthermore, administration of testosterone
to transgenic female SBMA mice exacerbates disease phenotype
(Katsuno et al., 2002), as does giving testosterone to male SBMA
mice treated with leuprorelin, a lutenizing hormone-releasing
hormone (LHRH) analog (Katsuno et al., 2003).
For years, many patients with SBMA received testosterone
treatment. The rationale for this treatment was complex, but a
partial loss of AR function coupled with the known anabolic effects
on muscle suggested that testosterone might prove beneficial
(Sheffield-Moore, 2000). Despite the evidence indicating that
testosterone contributes to the progression of SBMA, these patients
have not reported any negative effects as a result of androgen
administration (Goldenberg and Bradley, 1996; Neuschmid-Kaspar
et al., 1996). However, one case study reported on the substantial
decline of a patient with SBMA, with subsequent recovery upon
cessation of testosterone treatment (Kinirons and Rouleau, 2008).
However, the fact that this patient was taking paroxetine, a selective
serotonin reuptake inhibitor (SSRI), might complicate the
interpretation of this case. Paroxetine has been shown to enhance
the conversion of dihydrotestosterone (DHT) to androstanediol
(Griffin and Mellon, 1999), and thus there might have been
relatively low relative levels of DHT within his spinal motor
neurons. Treatment of this patient with testosterone might have
restored his DHT levels and exacerbated disease. Whether the same
would occur in SBMA patients not treated with paroxetine is
unknown.
Previously, we created and characterized mice that were
transgenic for the full-length expanded human AR gene, containing
112 CAG repeats, driven by the prion protein (PrP) promoter
(AR112Q mice) (Chevalier-Larsen et al., 2004). The disease in this
model progresses slowly, with AR112Q males beginning to exhibit
mild motor dysfunction at 3 months of age and developing late-
stage disease by 10 months of age (Chevalier-Larsen et al., 2004).
Furthermore, lifespan is unaffected. In the current study, we treated
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SUMMARY
Evidence from multiple animal models demonstrates that testosterone plays a crucial role in the progression of symptoms in spinal and bulbar
muscular atrophy (SBMA), a condition that results in neurodegeneration and muscle atrophy in affected men. Mice bearing a transgene encoding
a human androgen receptor (AR) that contains a stretch of 112 glutamines (expanded polyglutamine tract; AR112Q mice) reproduce several aspects
of the human disease. We treated transgenic male AR112Q mice with testosterone for 6 months. Surprisingly, testosterone treatment of AR112Q
males did not exacerbate the disease. Although transgenic AR112Q males exhibited functional deficits when compared with non-transgenics, long-
term testosterone treatment had no effect on motor function. Testosterone treatment also failed to affect cellular markers of disease, including
inclusion formation (the accumulation of large nuclear aggregates of mutant AR protein) and levels of unphosphorylated neurofilament heavy chain.
These data suggest that the mechanism of disease in SBMA saturates at close to endogenous hormone levels and that individuals with SBMA who
take, or have taken, testosterone for its putative therapeutic properties are unlikely to suffer adverse effects.
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Fig. 1. Disease phenotype is unaffected by testosterone treatment. (A)Testosterone treatment resulted in elevated serum testosterone levels in transgenic
(tg) T-treated (n8) and non-transgenic (ntg) T-treated (n10) animals when compared with tg sham-treated (n6) mice (P<0.05), with the exception of months
three and six. Although, testosterone levels dropped at the end of pellet life, testosterone levels were still significantly elevated in ntg T-treated mice in month six
and there was a trend towards elevated testosterone in tg T-treated animals. (B)Ability to remain on a rotarod was impaired in AR112Q T-treated (n10) and
AR112Q sham-treated (n12) males when compared with T-treated non-transgenics (n14) (P<0.05), but rotarod performance was similar between T-treated
AR112Q males and sham-treated AR112Q males (P>0.05). (C-E)Grip strength [using forepaws (C) or all paws (D)] and vertical activity (E) of all AR112Q males was
reduced in comparison to T-treated non-transgenic males (P<0.05), but no significant decrease in any of these measures was observed upon T-treatment of
AR112Q males (P>0.05). (F)Clasping behavior increased with age in all AR112Q males and was not affected by T-treatment; non-transgenic males rarely showed
clasping behavior.
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a cohort of these AR112Q male mice with testosterone, beginning
at 2 months of age, for a period of 6 months. Behavioral and
histopathological measures of disease indicate no change in severity
or age of onset of disease with testosterone treatment (T-treatment).
These data have important clinical implications for patients and
suggest that there is a point at which the role of hormone in the
pathogenic mechanism of SBMA becomes saturated.
RESULTS
Transgenic AR112Q and non-transgenic mice were implanted with
timed-release pellets designed to deliver 4-6 ng/ml of testosterone
for 90 days. Over the course of the experiment, implantation of
testosterone pellets increased circulating testosterone an average
of threefold, from 0.40±0.23 ng/ml (AR112Q sham-treated; n10)
to 1.26±0.48 ng/ml [non-transgenic (ntg) T-treated; n8] and
1.17±0.35 ng/ml [transgenic (tg) T-treated; n6]; this is a significant
elevation of testosterone levels in treated animals (ntg T-treated
and tg T-treated) over those implanted with placebo pellets (tg
sham-treated) (P<0.001). Although 90-day testosterone pellets
were used, we observed a decline in potency of the pellets by the
end of the 90-day period (months three and six) (Fig. 1A).
Implantation of new pellets at the end of 90 days restored circulating
testosterone levels (Fig. 1A).
Although circulating testosterone was elevated in treated mice,
motor function assays did not reveal any effect of testosterone
treatment on phenotype. Motor function assays were performed
monthly for 6 months; results were consistent for all 6 months of
treatment. Beginning at 3 months of age (1 month following
treatment), AR112Q males showed decreased rotarod performance,
regardless of T-treatment, when compared with non-transgenic T-
treated males (Fig. 1B). Decreased grip strength was apparent in
all AR112Q animals, regardless of T-treatment, when animals
gripped with either forepaws only (Fig. 1C) or all paws (Fig. 1D).
As previously observed (Chevalier-Larsen et al., 2004), weakness
was more pronounced when assessing all paws, implying greater
weakness in the hindlimbs. Vertical activity, or rearing behavior,
was also reduced in AR112Q males (Fig. 1E), although no deficits
were seen in T-treated AR112Q males when compared with sham-
treated AR112Q males. Clasping behavior was greater in both T-
treated and sham-treated AR112Q males when compared with T-
treated non-transgenic mice and increased steadily with time (Fig.
1F). T-treatment had no effect on weight or survival and no gross
alterations in muscle fiber morphology were observed (data not
shown).
Cellular markers of disease were also examined in spinal cord
and brain tissue to determine whether T-treatment expedited
cellular dysfunction that might not be detected by behavioral
changes. As with the behavioral analyses, no changes were detected
between the T-treated and sham-treated AR112Q males. NIIs were
present in both T-treated and sham-treated males; NII size and
frequency were similar between these two groups (Fig. 2A). A total
of 49.6±6.5% of motor neurons from lumbar spinal cord contained
NIIs in tg sham-treated animals, whereas NIIs were seen in
48.5±10.5% of motor neurons in tg T-treated mice (Fig. 2B). T-
treated non-transgenic mice did not exhibit NIIs (Fig. 2A). Similarly,
the level of unphosphorylated neurofilament heavy chain (NF-H)
was reduced in the neuronal soma of all AR112Q animals when
compared with non-transgenic mice (Fig. 2A), and the extent to
which unphosphorylated NF-H immunoreactivity was reduced was
similar between all AR112Q animals, regardless of T-treatment (Fig.
2C). In summary, signs of cellular pathogenesis were consistent with
those observed during characterization of this disease model and
were unchanged by long-term treatment with testosterone.
DISCUSSION
Although it is clear that testosterone plays a key role in SBMA
pathogenesis, the mechanism leading to neurodegeneration
remains unknown, although an increased understanding of the
specific aspects of AR metabolism that contribute to its misfolding,
aggregation and toxicity have come to light in recent years (Montie
et al., 2009; Nedelsky et al., 2010; Orr et al., 2010). The data from
this study suggest that, whatever the mechanism that leads to
neuronal dysfunction, there is a threshold at which the effect of
testosterone on this pathway plateaus. One possibility is that this
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Fig. 2. Testosterone treatment does not alter cellular disease
markers. NIIs were detected with AR-H280 antibody in spinal cord
of all AR112Q males (A, top); no differences in NII frequency were
detected upon T-treatment (B; n2). Nuclei of non-transgenic (ntg)
T-treated males show diffuse nuclear AR and no NIIs (A).
Unphosphorylated NF-H, as detected by SMI32 immunostaining (A,
bottom), was abundant in neuronal soma of the non-transgenic
spinal cord but was reduced in AR112Q tissue. (C)Quantification of
SMI32 intensity did not reveal any differences between transgenic
(tg) T-treated and tg sham-treated males (n2). Panels showing NIIs
(A, top) and SMI32 (A, bottom) are not from the same fields. Insets in
A represent the location within the anterior horn from which
higher-magnification images were taken (yellow box). The red oval
outlines the central canal, with the dorsal aspect to the left and the
ventral aspect to the right.
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threshold is due to saturation of AR with ligand. Our AR112Q mice
overexpress human AR. It is therefore likely that testosterone would
have a greater capacity to exert its pathogenic effects in AR112Q
mice than in SBMA patients expressing normal levels of AR.
Despite their increased capability to bind ligand, testosterone in
excess of endogenous levels had little effect on phenotypic or
cellular markers of disease progression.
Several previous studies have demonstrated that hormone
withdrawal can ameliorate disease onset and/or progression
(Katsuno et al., 2002; Katsuno et al., 2003; Chevalier-Larsen et al.,
2004; Li et al., 2007). It is possible that the brief decline in elevated
testosterone levels seen at the end of month three of these studies
might alleviate any adverse effects of hormone treatment. This
seems unlikely, however, because behavioral improvement due to
androgen ablation was not observed in mice of a comparable age
until 3 months following castration (Chevalier-Larsen et al., 2004)
and elevated testosterone levels were restored in month four,
following pellet re-implantation.
A caveat to the studies reported here is that our transgenic mice
express the mutant AR primarily in the nervous system, through
the use of the PrP promoter, and thus the evaluation of the mutant
protein (and added testosterone) in muscle, which plays an
important role in disease pathogenesis (Yu et al., 2006; Monks et
al., 2007), is limited. However, expression of the PrP-promoter-
driven transgene in muscle was observed, albeit at levels lower than
those in neural tissue (Chevalier-Larsen et al., 2004), and nuclear
inclusions in muscle were also noted (data not shown). Whether
testosterone treatment would exacerbate disease through effects
on muscle is unknown, although we find the possibility of different
pathogenic processes in motor neurons and muscle unlikely.
Mutant AR protein might exert its toxic effects on neurons
through multiple pathways, including disruption of protein folding
homeostasis, interference with protein degradation, transcriptional
dysregulation and/or by inhibition of axonal transport. It is possible
that a threshold level of mutant AR present in the nucleus would
lead to maximal disruption of neuronal function. In motor neurons,
testosterone and DHT have been shown to downregulate AR
expression (Vismara et al., 2009); thus, an excess of these ligands
might actually moderate the prevalence of the mutant AR. It is likely
that DHT, not testosterone, is the ligand responsible for neuronal
pathology in SBMA, given the high motor neuron levels of the
testosterone-to-DHT converting enzyme 5-reductase (Pozzi et al.,
2003). In this case, the conversion of testosterone to DHT via 5-
reductase could represent a point of saturation in the pathological
pathway. This hypothesis is particularly attractive because it would
suggest a mechanism for cell-type specificity in SBMA. However,
manipulation of 5-reductase activity with the inhibitor dutasteride
failed to modulate disease in SBMA patients (Fernandez-Rhodes
et al., 2011) or in a transgenic mouse model of SBMA (Maria Cho,
Heather Montie, Mary Rosemiller, Yuhong Liu and D.E.M.,
unpublished results). Regardless of the molecular mechanism by
which this saturation occurs, our data are encouraging in that
SBMA patients who had previously taken supplemental
testosterone are unlikely to have exacerbated their disease.
METHODS
Genotyping was performed as described previously (Chevalier-
Larsen et al., 2004).
2-month-old male mice were anesthetized with inhaled
isofluorane (3%). The area between the shoulder blades was shaved
and the surgical area sterilized with alcohol. A small (1-2 cm) dorsal
midline incision was made. A blunt probe was inserted into the
incision to create a subcutaneous pocket. A pellet containing a 90-
day-release 12.5 mg testosterone pellet or a placebo pellet (both
from Innovative Research of America) was placed into the pocket
and the incision was closed with a wound clip. Wound clips were
removed 3 days later. Mice were re-implanted with hormone or
sham pellet once during the course of this study. All animal
surgeries were performed according to the guidelines of the Office
of Laboratory Animal Welfare (OLAW) and the Institutional
Animal Care and Use Committee (IACUC) at Thomas Jefferson
University.
Blood samples were obtained monthly from each animal via
retro-orbital eye bleed. Sera were assessed for circulating
testosterone levels using a colorimetric EIA kit (Caymen Chemical)
according to the manufacturer’s instructions.
All behavioral assays were conducted monthly following pellet
implantation. Testing was carried out as previously described
(Chevalier-Larsen et al., 2004). An Ugo Basile (Italy) rotarod was
used.
Immunofluorescence of brain and spinal cord tissue was carried
out as previously described (Chevalier-Larsen et al., 2004).
Antibodies used include AR H280 (1:100; Santa Cruz) and SMI32
(1:1000; Sternberger Monoclonal). Motor neurons of the lumbar
spinal cord were scored as inclusion-positive whether they had
dmm.biologists.org144
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TRANSLATIONAL IMPACT
Clinical issue
Spinal and bulbar muscular atrophy (SBMA) is a neurodegenerative disorder
that is caused by a polyglutamine expansion in the androgen receptor (AR)
and affects approximately 1 in every 40,000 men. Affected men typically
develop muscle weakness of the proximal limbs and bulbar muscle, tremors
and fasciculations in mid-life. Muscle cramping can precede clinical symptoms.
Signs of androgen insensitivity, such as gynecomastia and reduced fertility,
often accompany muscle deficits. Female carriers of the disease are protected
both by X-inactivation of the gene encoding the mutant AR and by lower
levels of circulating AR ligands (testosterone and dihydrotestosterone). Prior to
the discovery that disease pathogenesis is androgen-dependent, many
individuals with SBMA received androgens therapeutically, based on the
assumption at the time that a loss of AR function contributed to disease
symptoms.
Results
This study examines the impact of exogenous testosterone on disease
progression in a mouse model of SBMA to determine whether testosterone
treatment of the patient population might in fact have exacerbated the
disease. The data indicate that the addition of exogenous testosterone does
not exacerbate disease progression in intact male mice that are transgenic for
a mutant AR. Behavioral measures of disease in testosterone-treated
transgenic males are indistinguishable from transgenic males that are sham
treated. Additionally, cellular markers of disease in testosterone-treated
transgenic males are comparable to those in sham-treated transgenic males.
Implications and future directions
These data suggest that it is unlikely that androgen therapy has hastened the
progress of disease in SBMA patients. They also suggest that there is a
threshold at which the contribution of testosterone to disease pathogenesis
becomes saturated.
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several punctate or single, large inclusions. Unphosphorylated
neurofilament immunoreactivity was quantified using ImageJ
software; integrated density values were acquired for regions of
interest delineated around motor neuron soma of the lumbar spinal
cord.
FUNDING
This work was supported by the National Institutes of Health [grant R01 NS32214]
to D.E.M.
AUTHOR CONTRIBUTIONS
E.S.C.-L. and D.E.M. conceived and designed the experiments, analyzed the data,
and wrote the manuscript. E.S.C.-L. performed the experiments.
REFERENCES
Chevalier-Larsen, E. S., O’Brien, C. J., Wang, H., Jenkins, S. C., Holder, L.,
Lieberman, A. P. and Merry, D. E. (2004). Castration restores function and
neurofilament alterations of aged symptomatic males in a transgenic mouse model
of spinal and bulbar muscular atrophy. J. Neurosci. 24, 4778-4786.
Ferlini, A., Patrosso, M. C., Guidetti, D., Merlini, L., Uncini, A., Ragno, M., Plasmati,
R., Fini, S., Repetto, M., Vezzoni, P. et al. (1995). Androgen receptor gene (CAG)n
repeat analysis in the differential diagnosis between Kennedy Disease and other
motoneuron disorders. Am. J. Med. Genet. 55, 105-111.
Fernandez-Rhodes, L. E., Kokkinis, A. D., White, M. J., Watts, C. A., Auh, S., Jeffries,
N. O., Shrader, J. A., Lehky, T. J., Li, L., Ryder, J. E. et al. (2011). Efficacy and safety
of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised
placebo-controlled trial. Lancet Neurol. 10, 140-147.
Goldenberg, J. N. and Bradley, W. G. (1996). Testosterone therapy and the
pathogenesis of Kennedy’s disease (X-linked bulbospinal muscular atrophy). J.
Neurol. Sci. 135, 158-161.
Griffin, L. D. and Mellon, S. H. (1999). Selective serotonin reuptake inhibitors directly
alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA 96, 13512-
13517.
Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Sang, C.,
Kobayashi, Y., Doyu, M. and Sobue, G. (2002). Testosterone reduction prevents
phenotypic expression in a transgenic mouse model of spinal and bulbar muscular
atrophy. Neuron 35, 843-854.
Katsuno, M., Adachi, H., Doyu, M., Minamiyama, M., Sang, C., Kobayashi, Y.,
Inukai, A. and Sobue, G. (2003). Leuprorelin rescues polyglutamine-dependent
phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy.
Nat. Med. 9, 768-773.
Kennedy, W. R., Alter, M. and Sung, J. H. (1968). Progressive proximal spinal and
bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology 18, 671-
680.
Kinirons, P. and Rouleau, G. A. (2008). Administration of testosterone results in
reversible deterioration in Kennedy’s disease. J. Neurol. Neurosurg. Psychiatry 79, 106-
107.
La Spada, A. R., Wilson, E. M., Lubahn, D. B., Harding, A. E. and Fischbeck, K. H.
(1991). Androgen receptor gene mutations in X-linked spinal and bulbar muscular
atrophy. Nature 353, 77-79.
Li, M., Miwa, S., Kobayashi, Y., Merry de Yamamoto, M., Tanaka, F., Doyu, M.,
Hashizume, Y., Fischbeck, K. H. and Sobue, G. (1998). Nuclear inclusions of the
androgen receptor protein in spinal and bulbar muscular atrophy. Ann. Neurol. 44,
249-254.
Li, M., Chevalier-Larsen, E. S. and Merry de Diamond, M. I. (2007). Soluble androgen
receptor oligomers underlie pathology in a mouse model of SBMA. J. Biol. Chem. 5,
3157-3164.
Monks, D. A., Johansen, J. A., Mo, K., Rao, P., Eagleson, B., Yu, Z., Lieberman, A. P.,
Breedlove, S. M. and Jordan, C. L. (2007). Overexpression of wild-type androgen
receptor in muscle recapitulates polyglutamine disease. Proc. Natl. Acad. Sci. USA 104,
18259-18264.
Montie, H. L., Cho, M. S., Holder, L., Liu, Y., Tsvetkov, A. S., Finkbeiner, S.  and
Merry, D. E. (2009). Cytoplasmic retention of polyglutamine-expanded androgen
receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar
muscular atrophy. Hum. Mol. Genet. 18, 1937-1950.
Nedelsky, N. B., Pennuto, M., Smith, R. B., Palazzolo, I., Moore, J., Nie, Z., Neale, G.
and Taylor, J. P. (2010). Native functions of the androgen receptor are essential to
pathogenesis in a Drosophila model of spinal and bulbar muscular atrophy. Neuron
67, 936-952.
Neuschmid-Kaspar, F., Gast, A., Peterziel, H., Schneikert, J., Muigg, A., Ransmayr,
G., Klocker, H., Bartsch, G. and Cato, A. C. B. (1996). CAG-repeat expansion in
androgen receptor in Kennedy’s disease is not a loss of function mutation. Mol. Cell.
Endocrinol. 177, 149-156.
Orr, C. R., Montie, H. L., Liu, Y., Bolzoni, E., Jenkins, S. C., Wilson, E. M., Joseph, J.
D., McDonnell, D. P. and Merry, D. E. (2010). An interdomain interaction of the
androgen receptor is required for its aggregation and toxicity in spinal and bulbar
muscular atrophy. J. Biol. Chem. 285, 35567-35577.
Pozzi, P., Bendotti, C., Simeoni, S., Piccioni, F., Guerini, V., Marron, T. U., Martini, L.
and Poletti, A. (2003). Androgen 5-alpha-reductase type 2 is highly expressed and
active in rat spinal cord motor neurones. J. Neuroendocrinol. 15, 882-887.
Schmidt, B. J., Greenberg, C. R., Allingham-Hawkins, D. J. and Spriggs, E. L. (2002).
Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two
homozygous women. Neurology 59, 770-772.
Sheffield-Moore, M. (2000). Androgens and the control of skeletal muscle protein
synthesis. Ann. Med. 32, 181-186.
Stenoien, D. L., Cummings, C. J., Adams, H. P., Mancini, M. G., Patel, K., DeMartino,
G. N., Marcelli, M., Weigel, N. L. and Mancini, M. A. (1999). Polyglutamine-
expanded androgen receptors form aggregates that sequester heat shock proteins,
proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone.
Hum. Mol. Genet. 8, 731-741.
Takeyama, K., Ito, S., Yamamoto, A., Tanimoto, H., Furutani, T., Kanuka, H., Miura,
M., Tabata, T. and Kato, S. (2002). Androgen-dependent neurodegeneration by
polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35, 855-
864.
Vismara, G., Simonini, F., Onesto, E., Bignamini, M., Miceli, V., Martini, L. and
Poletti, A. (2009). Androgens inhibit androgen receptor promoter activation in
motor neurons. Neurobiol. Dis. 33, 395-404.
Walcott, J. L. and Merry, D. E. (2002). Ligand promotes intranuclear inclusions in a
novel cell model of spinal and bulbar muscular atrophy. J. Biol. Chem. 277, 50855-
50859.
Yu, Z., Dadgar, N., Albertelli, M., Gruis, K., Jordan, D., Robins, D. M. and
Lieberman, A. P. (2006). Androgen-dependent pathology demonstrates myopathic
contribution to the Kennedy disease phenotyope in a mouse knock-in model. J. Clin.
Invest. 116, 2663-2672.
Disease Models & Mechanisms 145
Effects of testosterone in SBMA RESEARCH REPORT
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
